Seorin Bio is showing strong performance. It is interpreted that the news of its major client, Samsung Biologics, planning to invest over 1 trillion won to build Plant 5 has had an impact.
As of 9:27 AM on the 17th, Seorin Bio is trading at 11,870 won, up 1.89% compared to the previous day.
According to the industry, Samsung Biologics plans to invest more than 1 trillion won to construct Plant 5 in Songdo, Incheon. Earlier, in October last year, Samsung Biologics announced plans to establish a second campus and invest 7.5 trillion won in building Plants 5 and 6.
Plant 5 is expected to be built with an annual capacity of 180,000 liters. Currently, Plant 1 on the first campus has 30,000 liters, Plant 2 has 154,000 liters, Plant 3 has 180,000 liters, and Plant 4 has 240,000 liters. With the addition of Plant 5, the total capacity will reach 784,000 liters. This is the largest scale in the world for a contract development and manufacturing organization (CDMO) plant.
Meanwhile, Seorin Bio provides bio solutions to companies developing and producing vaccines, antibody-based therapeutics, cell therapies, immune cell therapies, blood products, and diagnostic reagents, as well as to schools, hospitals, research institutes, and public institutions. Samsung Biologics is known to be a major client.
In particular, Seorin Bio supplies highly exclusive raw materials related to cell culture media, as well as containers, mixers, and bioreactors, and is adopted in numerous biopharmaceutical pipelines of major domestic conglomerates and bio companies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
